Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 2

Status

Unknown 2Terminated 2Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 4NETWORK 3NIH 2

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 3Tumor-Agnostic 2Gastrointestinal 1Breast 1

Conditions

Neoplasms 2Carcinoma, Transitional Cell 2Stomach Neoplasms 1Muscle Invasive Bladder Cancer 1Breast Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × AZD4547 × Clear all
NCT02546661 2025-12-29

BISCAY

AstraZeneca

Phase 1 Active not recruiting
117 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

NCT05775874 2023-03-20

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Abbisko Therapeutics Co, Ltd

Phase 2 Unknown
80 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05086666 2021-10-21

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Abbisko Therapeutics Co, Ltd

Phase 1/2 Unknown
108 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT00979134 2019-03-15

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

AstraZeneca

Phase 1 Terminated
95 enrolled 19 charts
Tumor-Agnostic

Neoplasms

NCT01457846 2017-03-07

SHINE

AstraZeneca

Phase 2 Terminated
960 enrolled 13 charts
Gastrointestinal

Stomach Neoplasms

NCT01213160 2016-06-29

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

AstraZeneca

Phase 1 Completed
40 enrolled
Tumor-Agnostic

Neoplasms

NCT01202591 2016-02-11

GLOW

AstraZeneca

Phase 1/2 Completed
127 enrolled 8 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡